Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ORBIT
MCID: ORB013
MIFTS: 34

Orbital Disease (ORBIT)

Categories: Eye diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Orbital Disease

About this section

MalaCards integrated aliases for Orbital Disease:

Name: Orbital Disease 12 15
Orbital Diseases 44
Orbit 73

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:930
ICD10 33 H05 H05.9
ICD9CM 35 376 376.9
MeSH 44 D009916
SNOMED-CT 68 11270005
UMLS 73 C0029182
Sources

Summaries for Orbital Disease

About this section
Disease Ontology : 12 An adnexa disease that is located in the eye socket.

MalaCards based summary : Orbital Disease, also known as orbital diseases, is related to exophthalmos and intracranial sinus thrombosis, and has symptoms including visual disturbance and eye manifestations. An important gene associated with Orbital Disease is RHNO1 (RAD9-HUS1-RAD1 Interacting Nuclear Orphan 1). The drugs Methylprednisolone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include eye, ciliary ganglion and thyroid.

Wikipedia : 76 In anatomy, the orbit is the cavity or socket of the skull in which the eye and its appendages are... more...

Sources

Related Diseases for Orbital Disease

About this section

Diseases related to Orbital Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
# Related Disease Score Top Affiliating Genes
1 exophthalmos 29.6 RHNO1 TSHR
2 intracranial sinus thrombosis 10.2 PGBD1 RHNO1
3 cavernous sinus thrombosis 10.2 PGBD1 RHNO1
4 cranial nerve palsy 10.1 CHN1 RHNO1
5 esotropia 10.1 CHN1 TFAP2A
6 amblyopia 10.0 CHN1 TFAP2A
7 mastoiditis 10.0 CRP RHNO1
8 sphenoid sinusitis 10.0 CRP RHNO1
9 ethmoid sinusitis 10.0 CRP RHNO1
10 exotropia 10.0 CHN1 TNNI3K
11 subacute thyroiditis 10.0 CRP TSHR
12 congenital ptosis 10.0 CHN1 TNNI3K
13 tukel syndrome 10.0 CHN1 TNNI3K
14 pleural empyema 10.0 CRP PGBD1
15 ocular motility disease 9.9 CHN1 TNNI3K
16 subdural empyema 9.9 CRP PGBD1
17 duane retraction syndrome 9.9 CHN1 TNNI3K
18 immune system disease 9.9 CRP TSHR
19 orbital cellulitis 9.9 CRP PGBD1 RHNO1
20 acute orbital inflammation 9.9 CRP PGBD1 RHNO1
21 coloboma of macula 9.9 GDF3 TFAP2A
22 extrinsic cardiomyopathy 9.8 CRP TNNI3K
23 heart conduction disease 9.8 CRP TNNI3K
24 overnutrition 9.8 CRP TNNI3K
25 acquired metabolic disease 9.7 CRP TNNI3K
26 lymphoma 9.7
27 histiocytosis 9.7
28 hyperthyroidism 9.7
29 herpes zoster 9.7
30 herpes zoster ophthalmicus 9.7
31 enophthalmos 9.6 CHN1 EPB41L1 FAF2 TFAP2A TNNI3K
32 langerhans cell histiocytosis 9.6
33 mastitis 9.6
34 graves' disease 9.6
35 rhabdomyosarcoma 9.6

Graphical network of the top 20 diseases related to Orbital Disease:



Diseases related to Orbital Disease
Sources

Symptoms & Phenotypes for Orbital Disease

About this section

UMLS symptoms related to Orbital Disease:


visual disturbance, eye manifestations
Sources

Drugs & Therapeutics for Orbital Disease

About this section

Drugs for Orbital Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
2
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
3
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
5
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
6
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
7
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
8
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7553-56-2 807
9
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
10
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
11
Methimazole Approved Phase 4,Phase 1,Phase 2,Not Applicable 60-56-0 1349907
12
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
13
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
14
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
15
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
16
Bimatoprost Approved, Investigational Phase 4,Phase 3,Early Phase 1 155206-00-1 5311027
17
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1 1177-87-3
20
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
21
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
22
Methotrexate Approved Phase 4,Not Applicable 59-05-2, 1959-05-2 126941
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
24
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
28 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
32 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
36 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
39 Ophthalmic Solutions Phase 4,Phase 2
40 Viscosupplements Phase 4,Not Applicable
41 Adjuvants, Immunologic Phase 4,Not Applicable
42 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
43 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
44 Anesthetics, Local Phase 4,Phase 2,Phase 3,Not Applicable
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
46 Proxymetacaine Phase 4
47 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
50 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 132)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
2 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
3 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
4 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
5 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
6 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
7 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
8 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
9 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
10 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
11 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
12 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
13 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
14 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
15 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
16 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
17 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
18 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
19 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
20 Early Levothyroxine Post Radioactive Iodine Unknown status NCT01950260 Phase 2, Phase 3 Levothyroxine
21 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
22 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
23 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
24 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
25 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
26 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
27 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
28 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
29 Surgical Idiopathic Intracranial Hypertension Treatment Trial Recruiting NCT03501966 Phase 3 Acetazolamide
30 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
31 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
32 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg;Diclofenac Potassium 50 MG
33 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
34 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Active, not recruiting NCT03298867 Phase 3
35 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
36 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
37 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
38 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
39 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
40 Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial Unknown status NCT01119144 Phase 2
41 Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation Completed NCT00415506 Phase 1, Phase 2 Rituximab
42 Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED) Completed NCT00954057 Phase 2 LIPO-102;Placebo
43 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Completed NCT01727973 Phase 1, Phase 2 Doxycycline
44 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2 1α-D3;Placebos
45 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
46 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2 ATD Group
47 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
48 rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
49 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
50 Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Completed NCT00424151 Phase 1, Phase 2 Rituximab

Search NIH Clinical Center for Orbital Disease

Cochrane evidence based reviews: orbital diseases

Sources

Genetic Tests for Orbital Disease

About this section
Sources

Anatomical Context for Orbital Disease

About this section

MalaCards organs/tissues related to Orbital Disease:

41
Eye, Ciliary Ganglion, Thyroid, Testes, Heart

The Foundational Model of Anatomy Ontology organs/tissues related to Orbital Disease:

19
The Eye Socket
Sources

Publications for Orbital Disease

About this section

Articles related to Orbital Disease:

(show top 50) (show all 117)
# Title Authors Year
1
IgG4-related orbital disease. ( 29866378 )
2018
2
Diagnosis and Management of Pediatric Orbital Diseases. ( 29517648 )
2018
3
Treatment of Pediatric IgG4-Related Orbital Disease With TNF-I+ Inhibitor. ( 28700400 )
2017
4
IgG4-related orbital disease masquerading as thyroid eye disease, vice versa, or both? ( 29053038 )
2017
5
Incipient Ocular Mucosa-associated Lymphoid Tissue Lymphoma in IgG4-related Orbital Disease. ( 28367047 )
2017
6
Immunoglobulin G4-related orbital disease: An important differential diagnosis for orbital swellings with lymphoplasmacytic infiltration. ( 28937398 )
2017
7
Orbital Disease in Neuro-Ophthalmology. ( 27886890 )
2017
8
Infliximab for IgG4-Related Orbital Disease. ( 26784550 )
2016
9
IgG4 related orbital disease presenting with unilateral eyelid swelling. ( 27565007 )
2016
10
IgG4-related orbital disease mass lesion. ( 27085284 )
2016
11
Characteristics, diagnosis and therapeutic strategies for IgG4-related orbital disease. ( 27116895 )
2016
12
A case of non-lacrimal immunoglobulin G4 (IgG4)-related orbital disease with mastitis. ( 26700191 )
2016
13
Radiologic-pathologic correlation of orbital diseases. ( 27029808 )
2016
14
IgG4-related Orbital Disease and Its Mimics in a Western Population. ( 26379149 )
2015
15
Langerhans cell histiocytosis with presentation as orbital disease. ( 26167225 )
2015
16
Immunoglobulin G4-related orbital disease: report of two pediatric cases. ( 25897575 )
2015
17
Imaging of Pediatric Orbital Diseases. ( 26208421 )
2015
18
Management of Orbital Diseases. ( 26494502 )
2015
19
Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. ( 25341435 )
2014
20
Sequential biopsies from immunoglobulin G4-related orbital disease demonstrate progressive fibrosis. ( 24617918 )
2014
21
Kimura's disease of the lacrimal gland mimicking IgG4-related orbital disease. ( 25511019 )
2014
22
The meaning of diagnoses in orbital disease. ( 24022349 )
2013
23
Bilateral orbital and optic nerve endoscopic endonasal decompression for nonspecific inflammatory orbital disease: case report. ( 23042140 )
2013
24
Teaching neuroimages: IgG4-related orbital disease and enlargement of the trigeminal nerve branches. ( 24101754 )
2013
25
IgG4-related orbital disease: a meta-analysis and review. ( 22963447 )
2013
26
MAGNETIC RESONANCE IMAGING CONTRAST ENHANCEMENT OF EXTRA-OCULAR MUSCLES IN DOGS WITH NO CLINICAL EVIDENCE OF ORBITAL DISEASE. ( 23890158 )
2013
27
The usefulness of infraorbital nerve enlargement on MRI imaging in clinical diagnosis of IgG4-related orbital disease. ( 22644450 )
2012
28
Addition of a minimally invasive medial orbital approach in the endoscopic management of advanced sino-orbital disease: cadaver study with clinical correlations. ( 21271602 )
2011
29
Neuro-ophthalmology of orbital disease. ( 21601077 )
2011
30
Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease. ( 21242849 )
2011
31
Zolendronate associated inflammatory orbital disease. ( 20930911 )
2010
32
Spectrum of orbital disease in South India: an aravind study of 6328 consecutive patients. ( 20592641 )
2010
33
Image-guided transnasal endoscopic techniques in the management of orbital disease. ( 20807018 )
2010
34
Orbital disease in neuro-ophthalmology. ( 20637996 )
2010
35
Imaging for neuro-ophthalmic and orbital disease - a review. ( 19016810 )
2009
36
Intraocular pressure change in orbital disease. ( 19682621 )
2009
37
Application of tele-ophthalmology in remote diagnosis and management of adnexal and orbital diseases. ( 19700877 )
2009
38
Bilateral infiltrative orbital disease: is it chemically induced? ( 18982043 )
2008
39
Isolated upper eyelid retraction: a sign of idiopathic inflammatory orbital disease. ( 18209649 )
2008
40
Hyperthyroidism and severity of orbital disease do not change the central corneal thickness in Graves' ophthalmopathy. ( 18203097 )
2008
41
Severe, permanent orbital disease in herpes zoster ophthalmicus. ( 18716975 )
2008
42
Hyperthyroidism and severity of orbital disease do not change the central corneal thickness in Graves'' ophthalmopathy. ( 28221500 )
2008
43
Endoscopic sinus surgery for the management of orbital diseases. ( 18408413 )
2008
44
Assessment of ultrasonography and computed tomography for the evaluation of unilateral orbital disease in dogs. ( 17331049 )
2007
45
A personal view: probability in medicine, levels of (Un)certainty, and the diagnosis of orbital disease (with particular reference to orbital "pseudotumor"). ( 18071128 )
2007
46
Extraocular muscle quantification using mathematical morphology: a semi-automatic method for analyzing muscle enlargement in orbital diseases. ( 17081729 )
2007
47
Radiologic evaluation of lacrimal and orbital disease. ( 16982252 )
2006
48
Office evaluation of lacrimal and orbital disease. ( 16982254 )
2006
49
Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener's granulomatosis. ( 15774931 )
2005
50
Imaging for neuro-ophthalmic and orbital disease. ( 15531324 )
2004
Sources

Variations for Orbital Disease

About this section
Sources

Expression for Orbital Disease

About this section
Search GEO for disease gene expression data for Orbital Disease.
Sources

Pathways for Orbital Disease

About this section
Sources

GO Terms for Orbital Disease

About this section
Sources

Sources for Orbital Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....